A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells.

Por Halaschek-Wiener, J., Wacheck, V., Schlagbauer-Wadl, H., Wolff, K., Kloog, Y., Jansen, B.
Publicado em 2000

Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells

Por Wacheck, V, Selzer, E, Günsberg, P, Lucas, T, Meyer, H, Thallinger, C, Monia, B P, Jansen, B
Publicado em 2003

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

Por Cejka, D, Kuntner, C, Preusser, M, Fritzer-Szekeres, M, Fueger, B J, Strommer, S, Werzowa, J, Fuereder, T, Wanek, T, Zsebedics, M, Mueller, M, Langer, O, Wacheck, V
Publicado em 2009

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

Por Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr W, Valent P
Publicado em 2011-05-01